Verastem Oncology Reports Strong Progress in 2025 with Drug Launch, Pipeline Advances, and Financial Updates
Verastem Oncology reported its financial results for the fourth quarter and full year ending December 31, 2025, highlighting strong early revenue from its recently approved therapy, continued advancement of its oncology pipeline, and a solid financial position expected to support operations into 2027. The company, headquartered in Boston, focuses on developing targeted treatments for cancers driven by the RAS/MAPK signaling pathway.
The company’s performance in 2025 was marked by the accelerated approval and launch of its combination therapy AVMAPKI™ FAKZYNJA™ CO-PACK, along with progress in clinical development programs such as the investigational KRAS inhibitor VS-7375.
Launch of AVMAPKI FAKZYNJA CO-PACK Drives Initial Revenue
A major milestone for the company in 2025 was the accelerated approval from the U.S. Food and Drug Administration (FDA) for AVMAPKI FAKZYNJA CO-PACK in May 2025. The therapy, which combines avutometinib capsules with defactinib tablets, is the first treatment specifically approved for patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC).
Following its approval, the therapy quickly entered the commercial market in the United States and generated significant early revenue. For the fourth quarter of 2025, the treatment produced net product revenues of $17.5 million. For the full year, total product revenue reached $30.9 million.
The approval came approximately two months ahead of its scheduled regulatory decision date under the Prescription Drug User Fee Act (PDUFA), enabling Verastem Oncology to begin commercialization earlier than expected.
Company leadership noted that the therapy has been gaining traction among both gynecologic and medical oncologists. Physicians in academic centers as well as community practices are increasingly adopting the treatment for patients experiencing recurrent disease.
Positive Clinical Data from Japan Supports Therapy Profile
Clinical data from Japan further reinforced the therapy’s potential. Updated results from the RAMP 201J study, announced in February 2026, showed encouraging outcomes in patients with recurrent LGSOC.
Among the 16 patients enrolled in the study with a median follow-up of 10 months, the overall response rate reached 38%. In the subgroup of patients with KRAS-mutated recurrent disease, the response rate increased to 57%, with a disease control rate of 100%. Patients without KRAS mutations showed a response rate of 22% and a disease control rate of 89%.
Importantly, no patients discontinued treatment because of adverse events, and the safety profile observed in Japan was consistent with previously reported international data.
Clinical Guideline Developments and Ongoing Research
The therapy’s use is currently supported by treatment recommendations from the National Comprehensive Cancer Network (NCCN). The latest update of the NCCN Clinical Practice Guidelines for ovarian cancer maintained a category 2A recommendation for the combination therapy in patients with KRAS-mutated recurrent LGSOC.
However, the guidelines did not extend the recommendation to patients whose tumors lack KRAS mutations. Company leadership noted that these patients still lack targeted treatment options and often face poorer outcomes.
Verastem plans to continue building clinical evidence through ongoing trials and extended follow-up analyses. Data from the RAMP 201 study will be presented at the 2026 annual meeting of the Society of Gynecologic Oncology. Meanwhile, the confirmatory Phase 3 RAMP 301 trial is ongoing and includes patients with and without KRAS mutations. Topline results from this trial are expected in mid-2027.
The company is also pursuing regulatory opportunities to expand the therapy’s availability beyond the United States, including potential approvals in Europe and Japan.
Advancing VS-7375 for Multiple KRAS-Driven Cancers
Beyond its commercial therapy, Verastem Oncology continues to advance VS-7375, an oral KRAS G12D inhibitor designed to target one of the most common cancer-driving mutations. The investigational drug is being studied in several advanced solid tumors, including pancreatic, lung, and colorectal cancers.
Recent updates from the ongoing Phase 1/2 clinical study indicate that the drug has shown promising safety and tolerability results. Multiple dose levels—400 mg, 600 mg, and 900 mg once daily—have been cleared without dose-limiting toxicities. Researchers are now continuing dose escalation to 1200 mg to further assess safety and therapeutic activity.
In combination therapy studies, the 600 mg dose level of VS-7375 administered with cetuximab has also been cleared without dose-limiting toxicities, allowing investigators to evaluate higher doses.
Pharmacokinetic analyses suggest that exposure levels at doses of 600 mg or higher align with the levels required for maximum anti-tumor activity based on preclinical studies. Early patient data show that the drug has been generally well tolerated, with minimal severe side effects reported.
No drug-related liver function abnormalities have been observed, and severe gastrointestinal side effects have been limited.
Expansion of Clinical Trials Following Regulatory Feedback
Following discussions with the FDA, the company is revising its clinical trial strategy for VS-7375. The updated approach will involve separate Phase 2 registration-directed trials targeting specific cancer types.
The planned trials will focus on:
- Second-line pancreatic ductal adenocarcinoma (PDAC)
- Second- or third-line non-small cell lung cancer (NSCLC)
- Later-line colorectal cancer in combination with cetuximab
These studies aim to generate data that could support future regulatory filings.
Early efficacy signals have already emerged. Among five evaluable patients in the initial study cohort, four experienced tumor shrinkage and remained on treatment.
Development Progress in China Through Partner Collaboration
VS-7375 is also being developed in China through collaboration with partner GenFleet Therapeutics, where the drug is known as GFH375.
In March 2026, Chinese regulators granted the therapy Breakthrough Therapy Designation for the treatment of KRAS G12D-mutated non-small cell lung cancer after prior systemic therapy.
Clinical data from China have also been encouraging. In pancreatic cancer patients receiving the drug as a second-line treatment, response rates exceeded 50%, with disease control observed in all patients evaluated in that subgroup.
Meanwhile, a registrational Phase 3 trial has been initiated in China for patients with metastatic pancreatic cancer harboring KRAS G12D mutations.
Additional Pipeline Programs and Upcoming Milestones
Another ongoing study, RAMP 205, is evaluating the combination of avutometinib and defactinib with chemotherapy as a first-line treatment for metastatic pancreatic cancer.
Enrollment in the expansion cohort of this study was completed in the third quarter of 2025. Updated safety and efficacy results are expected in the second quarter of 2026 after at least six months of follow-up for all participants.
The company also plans several key development milestones for VS-7375 during 2026. These include early clinical data readouts, completion of enrollment in dose-escalation cohorts, and the launch of additional expansion cohorts across multiple cancer indications.
Corporate Developments and Leadership Changes
Verastem Oncology also reported several corporate developments during the year.
In December 2025, board member John Johnson was appointed chairman of the board. At the same time, Michael Kauffman, who had served as lead director since 2016, transitioned into the role of president of development.
The company also strengthened its financial position by completing a public offering of common stock and pre-funded warrants in November 2025, raising more than $96 million.
Fourth Quarter 2025 Financial Performance
For the fourth quarter of 2025, the company reported total operating expenses of $59 million, compared with $31.6 million during the same period in 2024.
Research and development expenses rose to $31.7 million, driven by increased manufacturing activities, clinical trial costs, and investigator fees associated with the company’s expanding development programs.
Selling, general, and administrative expenses totaled $24.4 million, reflecting commercialization costs tied to the launch of AVMAPKI FAKZYNJA CO-PACK.
The company recorded a net loss of $32.9 million for the quarter, or $0.39 per share, compared with a loss of $64.6 million, or $1.33 per share, in the prior-year period.
Full-Year 2025 Financial Results
For the full year, operating expenses reached $201 million, compared with $125 million in 2024. Research and development spending accounted for $114.6 million of the total, reflecting the continued advancement of the company’s clinical pipeline.
Selling, general, and administrative expenses totaled $81.1 million, primarily due to the commercialization activities surrounding the therapy’s launch.
Net loss for the year was $209.5 million, compared with $130.6 million in 2024.
Strong Cash Position Supports Future Development
As of December 31, 2025, Verastem Oncology held $205 million in cash, cash equivalents, and investments. After including proceeds from warrant exercises completed in January 2026, the company’s pro-forma cash balance increased to approximately $234 million.
Management expects this financial position, combined with ongoing product revenue, to provide sufficient funding to support operations into the first half of 2027.
Outlook for 2026 and Beyond
Looking ahead, Verastem Oncology plans to focus on expanding the adoption of AVMAPKI FAKZYNJA CO-PACK in the United States while advancing its next generation of targeted therapies.
The continued development of VS-7375 and upcoming clinical milestones across multiple cancer types will play a key role in the company’s long-term growth strategy.
With a recently launched therapy, a growing clinical pipeline, and a stable financial foundation, Verastem aims to further strengthen its position in the targeted oncology treatment landscape.
About AVMAPKI and FAKZYNJA Combination Therapy
AVMAPKI (avutometinib) inhibits MEK kinase activity while also blocking the compensatory reactivation of MEK by upstream RAF. RAF and MEK proteins are regulators of the RAS/RAF/MEK/ERK (MAPK) pathway. Blocking RAF and/or MEK activates FAK, a key mediator of drug resistance. FAKZYNJA (defactinib) is a FAK inhibitor and together, the avutometinib and defactinib combination was designed to provide a more complete blockade of the signaling that drives the growth and drug resistance of RAS/MAPK pathway-dependent tumors.
